Johnson & Johnson falls after pausing U.S. Varipulse cases

Johnson & Johnson offices in Silicon Valley

Sundry Photography/iStock Editorial via Getty Images

Sundry Photography

  • Johnson & Johnson (NYSE:JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets the cardiac disorder atrial fibrillation.
  • In reaction, its rivals in the PFA

Leave a Reply

Your email address will not be published. Required fields are marked *